FDA Grants Expanded Approval to Zongertinib for HER2-Mutant Lung Cancer
The FDA expanded accelerated approval for zongertinib in HER2-mutant NSCLC, marking a targeted therapy milestone for a hard-to-treat mutation.
Summary
The FDA has granted an expanded accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim) for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain activating mutations. This February 2026 expansion builds on an earlier August 2025 approval for patients who had already received prior systemic therapy, now broadening eligible patient populations. HER2-mutant NSCLC represents roughly 2–4% of all NSCLC cases and has historically lacked dedicated targeted options. Zongertinib is a selective, irreversible HER2 inhibitor designed to minimize off-target toxicity. Also notable: the combination of avutometinib plus defactinib received accelerated approval in May 2025 for KRAS-mutated recurrent low-grade serous ovarian cancer, reflecting a broader trend of precision oncology targeting previously undruggable mutations.
Detailed Summary
Precision oncology continues to advance rapidly, with the FDA granting accelerated approvals to targeted agents addressing mutations that were once considered difficult or impossible to drug effectively. Two recent approvals highlight this trend and carry meaningful implications for clinicians and patients alike.
Zongertinib (Hernexeos), developed by Boehringer Ingelheim, received its initial accelerated approval in August 2025 for unresectable or metastatic non-squamous NSCLC with HER2 (ERBB2) tyrosine kinase domain activating mutations in patients who had received prior systemic therapy. In February 2026, the FDA expanded this indication, potentially allowing earlier or broader use. HER2-mutant NSCLC affects an estimated 2–4% of NSCLC patients — a population that has historically been underserved by targeted therapies compared to EGFR- or ALK-driven disease.
Zongertinib is a next-generation, selective HER2 inhibitor engineered to reduce the off-target toxicity seen with earlier pan-HER inhibitors. Its accelerated approval pathway is based on response rate data, with confirmatory trials ongoing to verify clinical benefit in terms of survival outcomes.
Separately, the combination regimen of avutometinib plus defactinib (Avmapki Fakzynja Co-pack, Verastem) received accelerated approval in May 2025 for KRAS-mutated recurrent low-grade serous ovarian cancer following prior systemic therapy. KRAS mutations have long been considered a challenging oncology target, making this approval particularly significant for a rare and treatment-resistant cancer subtype.
For clinicians, these approvals signal an expanding toolkit for genomically defined cancers. Molecular profiling at diagnosis is increasingly essential to identify patients who may benefit. Caveats include the accelerated approval designation for both agents, meaning long-term survival data are still pending from confirmatory trials.
Key Findings
- Zongertinib received expanded FDA accelerated approval for HER2-mutant unresectable or metastatic non-squamous NSCLC in February 2026.
- Initial zongertinib approval in August 2025 targeted post-prior-therapy HER2-mutant NSCLC; the 2026 expansion broadens eligible patients.
- Avutometinib plus defactinib approved May 2025 for KRAS-mutated recurrent low-grade serous ovarian cancer after prior therapy.
- Both approvals are accelerated, based on response rates; confirmatory survival data are still pending.
- HER2-mutant NSCLC affects ~2–4% of NSCLC patients, a historically underserved population for targeted therapy.
Methodology
These are FDA accelerated approvals, typically granted based on surrogate endpoints such as objective response rate and duration of response rather than overall survival. Confirmatory randomized controlled trials are required post-approval to verify clinical benefit. Full trial methodology details were not available from the source abstract.
Study Limitations
This summary is based on the abstract and approval notification data only; full clinical trial data, safety profiles, and prescribing information were not reviewed. Both approvals are accelerated, meaning long-term efficacy and survival benefits remain to be confirmed in ongoing trials. No new oncology approvals were recorded in the April 22–May 6, 2026 window reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.